Seeking Alpha

Mylan (MYL -0.1%) says its subsidiary Mylan Pharmaceuticals has reached a settlement with...

Mylan (MYL -0.1%) says its subsidiary Mylan Pharmaceuticals has reached a settlement with Shionogi and Andrx to resolve patent litigation related to the generic version of Shionogi's Fortamet, an adjunct to diet and exercise to lower blood glucose. The terms of the settlement agreement are confidential, but has been disclosed it that MYL may launch a generic version of Fortamet on August 1, 2013, or earlier under certain conditions.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|